Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Ozempic Cuts Kidney Risk By 24%

Mar 05 2024

• By Elizabeth Cairns

Novo Nordisk HQ — • Source: Shutterstock

Related Content

The FLOW Of Novo Nordisk's Semaglutide Success Rolls Into Kidney Disease

Oct 11 2023

Related Companies

Novo Nordisk A/S

Eli Lilly and Company

AstraZeneca PLC

Fresenius Medical Care AG & Co. KGaA

Additional Topics

Clinical Trials Companies Research & Development Metabolic Disorders BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window